Buscador de publicaciones<< Volver
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, López-Sendón JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L
Apixaban versus warfarin in patients with atrial fibrillation.
N. Engl. J. Med.. 2011 Sep;365(11):981-92, PMID: 21870978
Vitamin K antagonists are highly effective in preventing stroke in patients with atrial fibrillation but have several limitations. Apixaban is a novel oral direct factor Xa inhibitor that has been shown to reduce the risk of stroke in a similar population in comparison with aspirin.
MEDICINE, GENERAL & INTERNAL
Una iniciativa de
